By train & bus +

Arriving at Zurich Airport, you reach us within less than an hour. Take the S2 train in direction to “Ziegelbrücke” and exit at “Horgen” or any train to Zurich Main Station, from where you choose either the S2 or S8 train to “Horgen”. In Horgen take Bus 121 until the “Risi/Dow” stop; our offices are a two minute walk from there.

For detailed train and bus schedules, please click here.

By car +

From Zurich take highway A3 in the direction of “Chur”. Take exit 36 “Wädenswil”, continue towards Wädenswil, cross the bridge and take the third exit at the roundabout. Carry on for about 3km and take a left into the Bachtobelstrasse and follow the signs to the L1 building. A car parking is located in front of the building. The reception is located on the third floor.

Overcoming limitations of existing approaches to uncover vast potential for new medicines

Our proprietary platforms λ-Cap™ and MATCH™ are designed to create differentiated therapeutics on a repeatable basis. Using a novel, rational process, our discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first-generation antibody therapies in terms of potency, stability, effect duration, and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Spearheading the development of first- and best-in-class high-impact therapeutics

We use validated discovery and engineering technologies to improve the predictability of the drug discovery process. We are establishing a proprietary pipeline of highly differentiated therapeutics by targeting clinically validated pathways with multispecific molecules to create novel mechanisms of action designed to overcome the limitations of existing approaches and differentiate from standard of care by superior efficacy and favorable safety.

Advancing our lead program NM26, a bispecific antibody targeting IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis and other type 2 inflammatory disorders

NM26-2198 is designed to prevent IL-4/IL-13 and IL-31-induced keratinocyte immunopathology, immune cell activation, skin barrier function impairment and pruritis, all of which are hallmarks of the pathophysiology of atopic dermatitis (AD). The targeting of the IL-4/IL-13 pathway is well established for the treatment of AD and other inflammatory diseases. We believe that adding IL-31 mediated blockade of neuroinflammation to the repression of Th2 driven inflammation by IL-4/IL-13 blockade could enable a faster onset of action and improved efficacy compared to the current standard of care in AD, together with convenient subcutaneous administration. Atopic Dermatitis still has a high unmet medical need and represents a multi-billion-dollar market opportunity. Numab develops this program together with Kaken Pharmaceutical Co., Ltd, our regional partner in Japan.

Establishing leading platform of next generation plug & play novel multispecific therapeutics.

Advancing a proprietary pipeline of next generation immunology and immuno-oncology drugs.

Developing the best MATCH for patients through plug & play assembly of novel multispecific biotherapeutics.

News

Pipeline

Overcoming limitations of existing approaches to uncover vast potential for new medicines

Spearheading the development of first- and best-in-class high-impact therapeutics

Advancing our lead program NM26, a bispecific antibody targeting IL-4Rα (type I and type II receptors) and IL-31 for the treatment of atopic dermatitis and other type 2 inflammatory disorders

Latest News

Stay informed.